Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2024.0991
Abstract: This randomized clinical trial investigates the effects of solanezumab and gantenerumab on downstream biomarkers in individuals with dominantly inherited Alzheimer disease. read more here.
Keywords: alzheimer disease; dominantly inherited; inherited alzheimer; downstream biomarker ... See more keywords
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
Sign Up to like & getrecommendations! Published in 2020 at "Nature Medicine"
DOI: 10.1038/s41591-020-0781-z
Abstract: Development of tau-based therapies for Alzheimer’s disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across… read more here.
Keywords: alzheimer disease; inherited alzheimer; disease; pathology ... See more keywords